Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions

NCT ID: NCT04875442

Last Updated: 2023-10-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-30

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety and performance study of the MemoWave electroencephalographic and sound recording device to increase slow brain waves during sleep to improve memory consolidation in subjects with mild cognitive impairment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

24 subjects aged between 40 and 85 years, presenting a mild cognitive disorder of the amnesic type (ie a memory complaint, a Mini Mental State ≥ 24 and a score ≤26 on free recall or ≤45 / 48 on total recall of the RLRI16 test) will be included;

Each patient spends 3 polysomnography nights at hospital: 1 night of habituation without Memowave device and next 2 nights with Memovave.

The device emits sounds to increase slow brain waves but Memowave emits sounds during only one of the two nights of test (night placebo vs night "verum"). The attribution of the night is randomized.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The device studied is worn during the 2 polysomnogaphy nights. The device emits sounds during only one night in order to observe the difference of EEG signals.

The night during which the device emits sounds is determined by randomization. The nature of the second night with the device, will be the reverse of the first, in a crossover fashion.
Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Memowave emitting sound

Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals

Group Type EXPERIMENTAL

Memowave emitting sounds

Intervention Type DEVICE

Memowave is worn during one night and emits sounds to increase slow brain waves

Memowave not emitting sound

Patients worn Memowave during one night, and the device doesn't emit sounds

Group Type PLACEBO_COMPARATOR

Memowave not emitting sounds

Intervention Type DEVICE

Memowave is worn during one night and doesn't emit sounds

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Memowave emitting sounds

Memowave is worn during one night and emits sounds to increase slow brain waves

Intervention Type DEVICE

Memowave not emitting sounds

Memowave is worn during one night and doesn't emit sounds

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject presenting a mild cognitive disorder of the amnesic type, defined by a memory complaint, a Mini Mental State ≥ 24 and a score ≤26 on free recall or ≤45 / 48 on total recall) of the RLRI16 episodic verbal memory test
* At least 7 years of schooling

Exclusion Criteria

* Severe psychiatric pathology
* Known neurological pathology
* High risk of apnea syndrome defined by at least 2 positive categories (each with a score ≥2) on the Berlin Questionnaire for Apnea Syndrome Screening
* High risk of behavioral disorder in REM sleep defined by an RBDSQ score\> 5.
* Taking sleeping pills or antidepressants
* Severe heart disease or unbalanced diabetes
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioSerenity

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ICM

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A01806-33

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Encoding for Memory
NCT00051870 COMPLETED
Brain and Mindfulness
NCT03117478 COMPLETED NA
Imaging Brain Fluids During Breathing
NCT05180981 RECRUITING NA